학술논문
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Document Type
Article
Author
Source
In The Lancet Gastroenterology & Hepatology August 2021 6(8):649-658
Subject
Language
ISSN
2468-1253